Recombinant Rat Receptor-type tyrosine-protein phosphatase epsilon (Ptpre)

What is Receptor-type tyrosine-protein phosphatase epsilon (PTPRE) and what are its key structural characteristics?

Receptor-type tyrosine-protein phosphatase epsilon (PTPRE) belongs to the receptor protein tyrosine phosphatase (RPTP) family, which functions as the enzymatic and functional counterpart of receptor protein tyrosine kinases (RPTKs). PTPRE plays a crucial role in regulating protein tyrosine phosphorylation, a fundamental post-translational modification controlling cell proliferation, differentiation, communication, and adhesion processes. The disruption of balance between protein tyrosine kinases and phosphatases, including PTPRE, can contribute to various diseases including cancer, diabetes, and autoimmune conditions .

Structurally, PTPRE possesses the characteristic organization of receptor-type phosphatases, with distinct extracellular, transmembrane, and intracellular domains. The extracellular domain (ECD) of PTPRE shares homology with cell adhesion molecules (CAMs). The intracellular domain contains two tandem PTP domains: a membrane-proximal domain (D1) that possesses most of the catalytic activity, and a membrane-distal domain (D2) with significantly weaker catalytic properties. This arrangement suggests that while D1 serves the primary enzymatic function, D2 likely plays a regulatory role rather than contributing substantially to catalysis .

The full-length rat PTPRE protein consists of 699 amino acids (excluding the first 22 amino acids of the signal peptide), with the mature protein spanning from amino acid 23 to 699. When expressed recombinantly with an N-terminal His-tag in E. coli, this protein provides researchers with a valuable tool for investigating PTPRE's enzymatic properties and interactions in controlled experimental settings .

What are the different isoforms of PTPRE and how do they differ functionally?

PTPRE exists in multiple isoforms that demonstrate tissue-specific expression patterns and distinct functional properties. The two primary isoforms include the membrane-bound form (memPTPRE) and the cytoplasmic form (cytPTPRE). The membrane-bound isoform contains the complete structural organization including the extracellular, transmembrane, and intracellular domains. In contrast, the cytoplasmic isoform lacks the extracellular and transmembrane domains, resulting in a soluble protein that localizes to the cytoplasm .

Research findings suggest that isoform expression is regulated in a tissue-specific manner, with different tissues exhibiting varying ratios of memPTPRE to cytPTPRE. This differential expression pattern likely contributes to tissue-specific functions of PTPRE, as observed in osteoclast cells, nerve cells, hematopoietic cells, and various cancer types. Understanding these isoform-specific differences is crucial for researchers designing experiments to investigate PTPRE function in specific cellular contexts .

How is PTPRE activity regulated in cellular environments?

PTPRE activity is regulated through multiple sophisticated mechanisms that allow for precise control of its phosphatase function in response to various cellular stimuli. One primary regulatory mechanism involves homodimerization through the D2 domain, which significantly inhibits its catalytic activity. This dimerization process is not constitutive but can be dynamically regulated by extracellular stimuli, including EGFR activation and increased oxidative stress, providing a mechanism for signal-responsive modulation of PTPRE activity .

Interaction with cytoskeletal elements represents another critical regulatory mechanism. Microtubules have been demonstrated to associate with PTPRE, and this association inhibits PTPRE's enzymatic activity. Importantly, disruption of microtubule structures releases this inhibition, alters PTPRE's subcellular localization, and consequently increases its phosphatase activity. Additionally, activation of EGFR has been shown to induce phosphorylation of Y638 in PTPRE, which enhances the association between microtubules and PTPRE, thereby reinforcing inhibition of PTPRE activity .

Post-translational modifications, particularly tyrosine phosphorylation, provide an additional layer of regulation. Research on related phosphatases like PTPRT has shown that tyrosine phosphorylation can significantly reduce phosphatase activity. For instance, phosphorylation of tyrosine 912 within the membrane-proximal catalytic domain of PTPRT by Fyn kinase reduces its phosphatase activity and reinforces homophilic interactions, preventing heterophilic interactions with binding partners like neuroligins . Similar regulatory mechanisms may apply to PTPRE, though specific sites and kinases may differ.

What experimental models are most appropriate for studying PTPRE function?

The selection of appropriate experimental models is crucial for investigating PTPRE function, with different systems offering distinct advantages depending on the research question. Cell culture models have been extensively employed, with studies utilizing various cell lines including neuronal cultures, cancer cell lines (particularly retinoblastoma lines like Y79 and WERI), and osteoclast cells. These in vitro systems allow for detailed molecular analyses, including protein-protein interactions, phosphatase activity assays, and subcellular localization studies through techniques such as confocal microscopy .

For studying PTPRE in cancer contexts, chemoresistant cell models have proven valuable. Research on retinoblastoma has employed etoposide-resistant cell lines (Y79_Etop and WERI_Etop) to investigate PTPRE's role in chemoresistance mechanisms. These models enable comparative analyses between chemosensitive and chemoresistant states, providing insights into how PTPRE expression and function change during acquisition of drug resistance .

In vivo models include the chicken chorioallantoic membrane (CAM) assay, which has been used to evaluate the effects of PTPRE knockdown on tumor formation capacity, size, and weight. This model represents an intermediate step between cell culture and mammalian models, offering a three-dimensional environment for tumor growth assessment while maintaining relative experimental simplicity .

For recombinant protein studies, E. coli expression systems have been successfully employed to produce full-length rat PTPRE protein with N-terminal His-tags. These recombinant proteins can be utilized in various biochemical assays, including phosphatase activity measurements, interaction studies, and structural analyses. When working with recombinant PTPRE, researchers should note specific handling recommendations, including avoiding repeated freeze-thaw cycles and proper reconstitution in appropriate buffers .

What are the key techniques for manipulating PTPRE expression and activity in experimental systems?

Effective manipulation of PTPRE expression and activity requires a sophisticated methodological toolkit that enables precise control in experimental systems. For downregulation of PTPRE, lentiviral-mediated knockdown approaches have proven particularly effective. Studies have successfully employed this technique to create stable PTPRE-depleted cell lines, with knockdown efficiency confirmable through quantitative real-time PCR and Western blot analysis. This approach has revealed significant functional consequences of PTPRE depletion, including decreased cell viability, reduced proliferation rates, and increased apoptosis in retinoblastoma cells .

Conversely, overexpression systems using plasmid vectors encoding wild-type or mutant PTPRE provide valuable tools for gain-of-function studies. Specifically, phosphorylation-mimic mutants (such as Y912E in the related phosphatase PTPRT) can be generated to investigate how post-translational modifications affect enzymatic activity. In vitro phosphatase assays conducted with these mutants have demonstrated significantly reduced catalytic activity, highlighting the regulatory importance of these modifications .

For more transient manipulations, microRNA-based approaches offer an alternative strategy. Research has demonstrated that miR631 can regulate PTPRE expression, with overexpression of this microRNA significantly decreasing PTPRE protein levels. This technique provides a complementary approach to genetic knockdown methods and can be particularly useful for investigating regulatory networks controlling PTPRE expression .

Pharmacological modulators of upstream pathways also represent valuable tools. For instance, inhibition of FGFR with compounds like Pemigatinib has been shown to influence cellular processes regulated by PTPRE, though direct effects on PTPRE expression were not consistently observed. Similarly, administration of recombinant FGF can be used to probe potential regulatory connections between growth factor signaling and PTPRE function, though results suggest this relationship may be context-dependent .

How does PTPRE interact with downstream signaling pathways and what are its key substrates?

Interestingly, despite the structural and functional similarities between PTPRE and other phosphatases, its substrate specificity appears distinct. For instance, while the related phosphatase PTPRT interacts with neuroligins to regulate synapse formation, similar interactions have not been extensively documented for PTPRE. PTPRT-induced synapse formation is attenuated by co-expression with the tyrosine kinase Fyn, and PTPRT mutants mimicking phosphorylation do not augment synapse formation, suggesting that tyrosine phosphorylation serves as a regulatory mechanism that may be shared with PTPRE .

The protein kinase SGK3 emerges as a particularly interesting potential PTPRE substrate or downstream effector. PTPRE knockdown consistently decreased phosphorylated SGK3 levels across different cell lines, suggesting a conserved regulatory relationship. This interaction appears to be functionally significant, as both PTPRE depletion and SGK3 inhibition yield similar phenotypic outcomes, including decreased cell viability and increased apoptosis in cancer cells .

What role does PTPRE play in cancer development and how might it be targeted therapeutically?

PTPRE demonstrates a complex role in cancer development, with particularly strong evidence for its oncogenic function in chemoresistant retinoblastoma. Expression analyses have revealed significantly higher PTPRE levels in etoposide-resistant retinoblastoma cell lines (Y79_Etop and WERI_Etop) compared to their chemosensitive counterparts. Similarly, PTPRE expression is elevated in retinoblastoma patient tumors relative to healthy human retina, suggesting clinical relevance of these findings .

Functional studies provide compelling evidence for PTPRE's pro-tumorigenic effects. Lentiviral-mediated PTPRE knockdown significantly decreases cell viability and proliferation while increasing apoptosis rates in etoposide-resistant retinoblastoma cells. Importantly, PTPRE depletion re-sensitizes resistant cells to etoposide treatment, indicating its potential role in chemoresistance mechanisms. In vivo chicken chorioallantoic membrane (CAM) assays have further demonstrated that PTPRE-depleted retinoblastoma cells develop significantly smaller tumors with lower weights compared to control cells, confirming the relevance of in vitro findings to three-dimensional tumor growth models .

Mechanistically, PTPRE appears to influence cancer progression through modulation of multiple signaling pathways. Knockdown experiments have revealed altered phosphorylation patterns of protein kinase SGK3 and, depending on the cell line, AKT and ERK1/2. These changes suggest that PTPRE may promote cancer cell survival and proliferation by regulating these critical signaling nodes. Additionally, the inverse relationship between miR631 and PTPRE expression in retinoblastoma suggests that downregulation of this microRNA may contribute to PTPRE overexpression in cancer contexts .

These findings collectively position PTPRE as a potential therapeutic target in cancer, particularly in chemoresistant contexts. Strategies for PTPRE inhibition might include small molecule inhibitors targeting its phosphatase activity, approaches to disrupt its protein-protein interactions, or methods to upregulate negative regulators like miR631. Given the evidence for PTPRE's role in chemoresistance, combination therapies incorporating PTPRE inhibition alongside conventional chemotherapeutics may represent a particularly promising approach, potentially restoring sensitivity to treatment-resistant tumors .

How do posttranslational modifications affect PTPRE function and what techniques are optimal for their study?

Posttranslational modifications (PTMs) play a crucial role in regulating PTPRE function, with tyrosine phosphorylation emerging as a particularly significant regulatory mechanism. Studies on the related phosphatase PTPRT have demonstrated that phosphorylation of tyrosine 912 within the membrane-proximal catalytic domain by Fyn kinase significantly reduces phosphatase activity and alters protein-protein interactions. In vitro phosphatase assays with a phosphorylation-mimic mutant (Y912E) of PTPRT showed severely reduced catalytic activity, highlighting the functional importance of this modification .

For PTPRE specifically, phosphorylation of Y638 has been documented following EGFR activation, enhancing the association between PTPRE and microtubules and consequently inhibiting PTPRE activity. This finding demonstrates how PTMs can regulate PTPRE function not only by directly affecting catalytic activity but also by modulating protein-protein interactions and subcellular localization .

Multiple techniques can be employed to investigate PTMs of PTPRE, each with specific advantages. Mass spectrometry-based phosphoproteomic approaches provide comprehensive identification of phosphorylation sites across the entire protein. Western blotting with phospho-specific antibodies (when available) offers a more targeted approach for monitoring specific modification sites. Additionally, the use of phosphorylation-mimic (e.g., Y to E) or phosphorylation-deficient (e.g., Y to F) mutants provides powerful tools for investigating the functional consequences of specific modifications .

In vitro kinase assays can identify enzymes capable of phosphorylating PTPRE, while in vitro phosphatase assays with purified recombinant proteins allow precise quantification of how specific modifications affect catalytic activity. For studying the dynamic regulation of PTMs in cellular contexts, inhibitors or activators of relevant kinases (e.g., EGFR inhibitors, Fyn inhibitors) can be employed to modulate modification states .

What are the methodological challenges in purifying and handling recombinant PTPRE for in vitro studies?

Working with recombinant PTPRE presents several methodological challenges that researchers must address to ensure experimental success. The full-length rat PTPRE protein consists of 677 amino acids (positions 23-699, excluding the signal peptide) and contains both hydrophobic transmembrane regions and multiple structural domains. This complex architecture can create difficulties in expression, purification, and handling processes that require specific technical considerations .

Expression systems represent a critical choice point, with E. coli being successfully employed for producing recombinant rat PTPRE. The addition of an N-terminal His-tag facilitates purification through affinity chromatography, though researchers should be aware that tags may potentially influence protein folding or activity. Quality control through SDS-PAGE is essential, with preparations typically achieving greater than 90% purity to ensure experimental reliability .

Storage considerations are particularly important for maintaining PTPRE activity and stability. The purified protein is commonly provided as a lyophilized powder, which requires proper reconstitution in deionized sterile water to a concentration of 0.1-1.0 mg/mL. To preserve activity during long-term storage, the addition of glycerol (typically 5-50% final concentration) is recommended, with aliquoting to avoid repeated freeze-thaw cycles. Storage buffer composition (typically Tris/PBS-based buffer with 6% Trehalose, pH 8.0) has been optimized to maintain protein stability .

Working with recombinant phosphatases requires specific precautions to prevent loss of enzymatic activity. Repeated freeze-thaw cycles should be strictly avoided, as they can denature the protein and reduce catalytic function. For routine laboratory use, working aliquots can be stored at 4°C for up to one week, but longer-term storage requires -20°C or -80°C conditions. Additionally, researchers should consider the potential interference of phosphatase inhibitors commonly present in cell lysis buffers when designing experiments to assess PTPRE activity in cellular contexts .

How can researchers effectively measure PTPRE enzymatic activity in experimental settings?

Accurately measuring PTPRE enzymatic activity requires careful selection and implementation of appropriate assay systems that address the specific properties of this phosphatase. In vitro phosphatase assays represent the gold standard for directly quantifying catalytic activity. These assays typically employ artificial substrates such as para-nitrophenylphosphate (pNPP) or phosphopeptides that mimic physiological substrates. The dephosphorylation reaction produces colorimetric or fluorescent signals that can be quantitatively measured using spectrophotometric techniques. When conducting these assays with recombinant PTPRE, researchers should carefully control buffer conditions, as pH, salt concentration, and the presence of reducing agents can significantly influence enzymatic activity .

For more physiologically relevant assessments, researchers can employ phospho-specific antibodies to monitor the phosphorylation status of known or potential PTPRE substrates following manipulation of PTPRE expression or activity. Western blot analyses have successfully utilized this approach to demonstrate that PTPRE knockdown alters the phosphorylation patterns of SGK3, AKT, and ERK1/2 in retinoblastoma cells. This method provides insights into substrate-specific effects in cellular contexts, complementing the more direct measurements obtained from in vitro assays .

Genetic approaches offer additional strategies for investigating PTPRE activity. The expression of catalytically inactive mutants (created by introducing mutations in critical catalytic residues) can serve as dominant-negative inhibitors of endogenous PTPRE function. Alternatively, phosphatase-dead mutants can be utilized as substrate traps, facilitating the identification of PTPRE substrates through co-immunoprecipitation followed by mass spectrometry analysis. This substrate-trapping approach has been particularly valuable for elucidating the functional interactions of protein tyrosine phosphatases .

What are the best experimental designs for studying PTPRE's role in cell signaling and disease models?

Designing robust experiments to investigate PTPRE's role in cell signaling and disease models requires thoughtful selection of model systems and implementation of complementary techniques that provide mechanistic insights. A multi-tiered experimental approach typically yields the most comprehensive understanding, beginning with expression profiling to establish the relevance of PTPRE in the chosen disease context. Quantitative PCR and Western blot analyses should be employed to compare PTPRE levels between normal and pathological states, as exemplified by studies demonstrating elevated PTPRE expression in retinoblastoma tumors compared to healthy retina tissue .

Gene manipulation studies represent the cornerstone of functional investigations. Lentiviral-mediated knockdown has proven particularly effective for creating stable PTPRE-depleted cell lines, with knockdown efficiency confirmable through quantitative PCR and Western blotting. These models enable comprehensive phenotypic characterization through assays measuring cell viability (WST-1), proliferation (BrdU incorporation), apoptosis (caspase activation), and growth kinetics (growth curve analyses). For gain-of-function studies, overexpression of wild-type or mutant PTPRE provides complementary insights, with phosphorylation-mimic mutants offering valuable tools for investigating regulatory mechanisms .

To establish physiological relevance, in vivo models represent an essential component of experimental design. The chicken chorioallantoic membrane (CAM) assay has been successfully employed as an intermediate model, allowing assessment of tumor formation capacity, size, and weight following manipulation of PTPRE expression. This system strikes a balance between experimental complexity and physiological relevance, providing three-dimensional growth conditions while maintaining relative technical simplicity .

For mechanistic investigations, signaling pathway analyses should be conducted using phospho-specific antibodies to monitor key nodes in relevant pathways. Western blot analyses have revealed that PTPRE depletion affects the phosphorylation status of SGK3, AKT, and ERK1/2 in a cell line-dependent manner, suggesting context-specific signaling effects. These findings should be complemented with functional rescue experiments, where the phenotypic consequences of PTPRE depletion are reversed by reintroduction of wild-type but not catalytically inactive PTPRE, confirming phosphatase activity as the critical mediator of observed effects .

How does PTPRE compare functionally with other receptor-type tyrosine phosphatases?

Receptor-type tyrosine phosphatases (RPTPs) constitute a diverse family with members exhibiting both structural similarities and functional specializations. PTPRE shares significant structural homology with PTPRA (Receptor type protein tyrosine phosphatase alpha), featuring similar domain organizations including extracellular domains with cell adhesion molecule-like motifs, a single transmembrane domain, and intracellular regions containing two tandem phosphatase domains. Despite these structural similarities, functional studies indicate distinct biological roles for these closely related phosphatases, highlighting the importance of empirical investigation rather than inferring function based solely on structural homology .

In contrast to PTPRE's association with cancer progression, particularly in retinoblastoma, other RPTPs demonstrate diverse functional properties. For instance, PTPRT/RPTPρ plays a crucial role in synapse formation through interactions with cell adhesion molecules and Fyn protein tyrosine kinase. Overexpression of PTPRT in cultured neurons increases the number of excitatory and inhibitory synapses by recruiting neuroligins that interact with PTPRT through their ecto-domains. Conversely, knockdown of PTPRT inhibits synapse formation and causes dendrite withering, demonstrating its critical role in neuronal development. This function appears distinct from PTPRE's documented roles, highlighting the functional diversity within the RPTP family .

Table 1: Comparison of Selected Receptor-Type Tyrosine Phosphatases

What is the relationship between PTPRE and microRNA regulation, and how can this be investigated?

The relationship between PTPRE and microRNA regulation represents an emerging area of research with significant implications for understanding PTPRE expression control in normal and pathological states. Studies in retinoblastoma have revealed an inverse correlation between miR631 expression and PTPRE levels. MiR631 is significantly downregulated in etoposide-resistant retinoblastoma cells and patient tumors compared to healthy human retina, while PTPRE displays opposing expression patterns in these same contexts. This inverse relationship suggests a potential regulatory connection that warrants detailed investigation .

Functional studies provide compelling evidence for direct regulatory control, as transient overexpression of miR631 results in significantly decreased PTPRE protein levels. Importantly, this miR631-mediated PTPRE downregulation produces functional consequences that mirror those observed following direct PTPRE knockdown, including significantly decreased proliferation rates and increased apoptosis levels. These findings strongly indicate that PTPRE expression in etoposide-resistant retinoblastoma is regulated by miR631, establishing this microRNA as an important upstream regulatory element .

Several experimental approaches can be employed to investigate this regulatory relationship. Bioinformatic prediction tools can identify potential miRNA binding sites within the PTPRE mRNA sequence, generating hypotheses regarding direct interaction mechanisms. Luciferase reporter assays using constructs containing the predicted binding sites can then experimentally validate these direct interactions. Site-directed mutagenesis of the putative binding sites should abolish the regulatory effect if the interaction is direct. Additionally, Argonaute immunoprecipitation followed by RNA sequencing (AGO-RIP-seq) can identify miRNA-mRNA complexes in cellular contexts, providing evidence for endogenous interactions .

To establish physiological relevance, researchers should examine the correlation between miR631 and PTPRE expression across diverse tissue samples, ideally including both normal and pathological specimens. In therapeutic contexts, the potential of miR631 mimics or delivery systems to suppress PTPRE expression and consequently modulate cancer cell phenotypes represents an intriguing avenue for translational investigation. The successful development of such approaches would establish a microRNA-based strategy for indirectly targeting PTPRE in cancer and potentially other disease contexts .